NCT07927816

A Single-Arm, Dose-Escalation Clinical Study on the Safety of CD19 Sequential CD22 In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Study Summary

This is a single-center, open-label, single-arm, prospective, investigator-initiated dose-escalation study to evaluate the safety, tolerability, preliminary efficacy, and cellular kinetics of an in vivo CAR-T cell immunotherapy targeting CD19 sequentially followed by CD22, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). The investigational product is a targeted lentiviral vector that transduces the patient's endogenous T/NK cells in situ; no leukapheresis, ex vivo manufacturing, or lymphodepleting conditioning is required. Participants receive an intravenous infusion of CD19-targeted in vivo CAR-T on Day 0, followed by an intravenous infusion of CD22-targeted in vivo CAR-T on Day 7. Before the Day 7 infusion, the investigator will assess each participant to determine whether the second infusion should proceed, based on: (i) the proportion of CAR-positive T/NK cells in peripheral blood, which reflects the success of in vivo transduction and early expansion after the first infusion; (ii) the maximum grade and current control of adverse events occurring after the first infusion, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS); and (iii) the participant's general condition, including Eastern Cooperative Oncology Group (ECOG) performance status and vital organ function (cardiac, hepatic, renal, pulmonary, and coagulation). The second infusion will be postponed or cancelled if any of these assessments indicates that the risk outweighs the benefit, for example grade \>=3 CRS or grade \>=2 ICANS that has not resolved to grade \<=1, or investigator-judged deterioration in organ function. Dose escalation follows a traditional 3+3 design with planned dose levels of 1×10\^9, 3×10\^9, and 6×10\^9 transducing units (TU), guided by dose-limiting toxicities (DLTs) assessed during Days 0-28; higher dose levels may be explored if the maximum tolerated dose is not reached. Treatment-emergent adverse events and serious adverse events, including CRS, immune effector cell-associated neurotoxicity syndrome (ICANS), hematologic toxicity, and organ toxicity, will be assessed. Preliminary antitumor activity will be evaluated by objective response rate (ORR), overall survival (OS), and progression-free survival (PFS), and the expansion and persistence of in vivo-generated CAR-T cells in peripheral blood will also be evaluated.

Interested in this trial?

Submit an Inquiry

Interventions

CD19-Targeted In Vivo CAR-T Injection (first infusion, Day 0); CD22 -Targeted In Vivo CAR-T Injection (second infusion, Day 7)DRUG
The investigational products are engineered lentiviral vector-based in vivo gene therapy products. The viral envelope receptor-binding domain has been mutated to abolish native pantropic infectivity, and a targeting module composed of an anti-CD7 nanobody (VHH) and a T/NK-cell-specific ligand (CD58 extracellular domain) has been incorporated into the envelope, enabling specific transduction of circulating T cells and NK cells in situ and expression of a chimeric antigen receptor directed against CD19 (first infusion, Day 0) or CD22 (second infusion, Day 7). No leukapheresis, ex vivo manufacturing, or lymphodepleting conditioning is required. Dose escalation follows a traditional 3+3 design with planned dose levels of 1×10\^9, 3×10\^9, and 6×10\^9 transducing units (TU), guided by the occurrence of dose-limiting toxicities (DLTs).

Study Locations

FacilityCityStateCountry
Chinese PLA General HospitalBeijingBeijing MunicipalityChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: November 22, 2026